The current P/E ratio of BMY cannot be calculated, as the latest EPS of -$3.09 is negative. The last PE ratio of Bristol Myers Squibb, recorded in December 2023, was 13.22.
The PE ratio of Bristol Myers Squibb has averaged 43.42 over the last ten years. Analyzing the last ten years, BMY's PE ratio reached its highest point in the Jun 2018 quarter at 221.36, when the price was $55.34 and the EPS was $0.25. The lowest point was recorded in the Jun 2019 quarter, when it reached 11.93 with a price of $45.35 and an EPS of $3.8.
Maximum annual increase: 358.93% in 2017
Maximum annual decrease: -82.81% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 13.22 | -45.44% |
| 2022 | 24.23 | 22.44% |
| 2021 | 19.79 | N/A |
| 2020 | N/A | N/A |
| 2019 | 31.78 | 84.02% |
| 2018 | 17.27 | -82.81% |
| 2017 | 100.46 | 358.93% |
| 2016 | 21.89 | -70.09% |
| 2015 | 73.18 | 49.99% |
| 2014 | 48.79 | 43.21% |
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.53 | $352.02B |
| NVS Novartis AG | 13.15 | $198.82B |
| AMGN Amgen Inc | 21.5 | $144.69B |
| ABT Abbott Laboratories | 32.78 | $186.58B |
| AZN Astrazeneca plc | 36.67 | $233.05B |
| ABBV AbbVie Inc | 58.47 | $281.96B |
| PFE Pfizer Inc | 66.84 | $143.43B |
| LLY ELI LILLY & Co | 126.03 | $696.96B |
| MRK Merck & Co Inc | 937.14 | $332.28B |
| BMY Bristol Myers Squibb Co | N/A | $90.92B |
The current price to earnings ratio of BMY cannot be determined, as its EPS of -$3.09 is negative.
The 3-year average PE ratio for BMY stock is 20.32.
The 5-year average PE ratio for BMY stock is 25.25.
Over the last ten years, the quarterly PE ratio reached its highest level at 221.36 in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.